Navigation Links
BioLife Solutions Announces License Agreement
Date:5/2/2013

BOTHELL, Wash., May 2, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced that it has licensed specific areas of its intellectual property to Janssen Research & Development, LLC (Janssen).

(Logo: http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO)

Mike Rice , Chief Executive Officer, said, "Our team has worked closely with Janssen for several years.  CryoStor has shown remarkable ability to maintain viability and function of numerous cell types following cryopreservation, a process that involves freezing cells to suspend metabolic activity to enable short and long term storage.  This is a critical component in optimizing the biopreservation economics of emerging regenerative medicine therapies where efficient, scalable, and consistent product delivery to a worldwide clinical patient population will strongly dictate commercial success if regulatory approvals are obtained."

The regenerative medicine market is expected to grow to more than $35 billion by 2019, according to TriMark Publications' newly published "Regenerative Medicine Markets" report.  BioLife's addressable portion of the market is the demand for reagents used to store, ship and freeze source material and manufactured doses of cell-based products and therapies.

About BioLife SolutionsBioLife Solutions develops, manufactures and markets hypothermic storage and cryopreservation solutions for cells, tissues, and organs.  The Company's proprietary HypoThermosol® and CryoStor® platform of solutions are marketed to academic and commercial organizations in the biobanking, drug discovery, and regenerative medicine markets. BioLife's products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death.  BioLife's enabling technology provides academic and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs.  For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact.  Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission.  BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.  Media Relations:Investor Relations:Len Hall

Matt ClawsonAllen & Caron Inc

Allen & Caron Inc(949) 474-4300

(949) 474-4300len@allencaron.com

matt@allencaron.com
'/>"/>

SOURCE BioLife Solutions, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BioLife Solutions Announces 2012 Third Quarter Results: Ninth Straight Quarter of Record Revenue
2. BioLife Solutions Announces Presentation at IBC Inaugural Cell Therapy Clinical Development Conference
3. BioLife Solutions Announces 2012 Second Quarter Results: Eighth Straight Quarter of Record Revenue
4. BioLife Solutions Completes Corporate Facilities Expansion, Build-Out of Additional cGMP Clean Room Manufacturing Suite
5. Improved Cord Blood Processing Research on BioLife Solutions CryoStor® Published in TRANSFUSION
6. BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board
7. BioLife Solutions 2011 Revenue Up 33%
8. BioLife Solutions Launches Search Engine Optimized Website and 1,000 Free Samples Offer
9. RiboSolutions Inc. Announces the Release of Cyanase™ Cell Lysis System and Cyanase™ Inactivation Cartridges to their Benzonase® Alternative Catalog
10. SPIE Counts Advances in Sustainable Photonics on List of Solutions to Celebrate on Earth Day
11. Finesse Solutions and ATMI Sign Distribution Agreement for Turnkey Bioreactor Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... Research and Markets has announced the addition ... - Industry Forecast to 2025" report to their offering. ... The Global Bioplastics ... around 12.8% over the next decade to reach approximately $8.9 billion ... estimates and forecasts for all the given segments on global as ...
(Date:2/20/2017)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ) announced today that ... Orecchioni, the company,s COO, has been named President, effective immediately.  ... years, Fabrice has overseen the construction, start-up and operation of the ... of the Mitsui JV.  Fabrice has also been extensively involved in ... ...
(Date:2/20/2017)... 2017 This report analyzes the worldwide markets for ... Xylanase, Amylase, Cellulase, and Others. The report provides separate comprehensive ... Japan , Europe , ... and Rest of World. Read the full ... are provided for the period 2015 through 2022. Also, a ...
(Date:2/20/2017)... ... February 20, 2017 , ... Cancer diagnostics and pathology workflow ... a unique precision medicine knowledge visualization and decision support platform. , The ... cockpit and is downloadable as an app for any mobile device and computer. ...
Breaking Biology Technology:
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis zum Jahr 2018 ... mehr als 50 Vertretern aus verschiedenen Branchen wurde aber klar, ... Prognose zu realisieren. ... Zu den Schwierigkeiten für Biobanking-Profis ... die Biobank, die Implementierung Zeit sparender Technologien, ein besseres ...
(Date:2/13/2017)... , Feb. 13, 2017 Former 9/11 Commission ... Judiciary Committee, Janice Kephart of Identity Strategy ... Donald Trump,s "Executive Order: Protecting the Nation ... 27, 2017):  "As President Trump,s ,Travel Ban, ... has now essentially banned the travel ban, it is ...
(Date:2/8/2017)... Feb. 7, 2017  Aware, Inc. (NASDAQ: AWRE ... reported financial results for its quarter and year ended December ... of 2016 was $3.9 million compared to $6.9 million in ... quarter of 2016 was $0.6 million compared to $2.6 million ... fourth quarter of 2016 was $0.5 million, or $0.02 per ...
Breaking Biology News(10 mins):